Zobrazeno 1 - 10 of 16 pro vyhledávání: '"J B Seidelin"'
1
P608 Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysis
Autor: M Attauabi, E K Dahl, J Burisch, J Gubatan, O H Nielsen, J B Seidelin
Publikováno v: Journal of Crohn's and Colitis. 17:i735-i738
Background Time to response of advanced therapies is an important parameter due to the symptom load and risk of disease complications in moderate-to-severe ulcerative colitis (UC), but comparative data are lacking. We aimed to assess the comparative
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b70a39276904701199bea2db71cfbf9a
https://doi.org/10.1093/ecco-jcc/jjac190.0738
Zobrazit plný text záznamu
2
P555 Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases
Autor: S Grimsdottir, M Attauabi, E K Dahl, J Burisch, J B Seidelin
Publikováno v: Journal of Crohn's and Colitis. 17:i683-i686
Background The association between cancer treatments and exacerbation of IBD is unclear. We aimed to evaluate the effects of cancer treatments on the disease activity of IBD. Methods We performed a systematic review of the literature on cancer therap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce78fcdd2748bc6c0188a3d22c16f9e3
https://doi.org/10.1093/ecco-jcc/jjac190.0685
Zobrazit plný text záznamu
3
P293 Correlation between clinical measures to capture disease burden and prediction of the initial course of Crohn’s disease - findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
Autor: M Attauabi, G R Madsen, F Bendtsen, J T Bjerrum, R Wilkens, K Theede, J F K F Ilvemark, T Boysen, J B Seidelin, J Burisch
Publikováno v: Journal of Crohn's and Colitis. 17:i437-i440
Background The initial disease burden of Crohn’s disease (CD) is dissimilar across patients; however, the ability to capture and predict the disease burden at diagnosis is scarcely investigated. The aim of the current study was to describe the init
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1877acf7d0f265e8c4b549cca8f9f1b8
https://doi.org/10.1093/ecco-jcc/jjac190.0423
Zobrazit plný text záznamu
4
DOP54 Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis
Autor: M Attauabi, C Steenholdt, J Burisch, J Gubatan, O H Nielsen, J B Seidelin
Publikováno v: Journal of Crohn's and Colitis. 17:i124-i126
Background Patients with moderately to severely active luminal Crohn’s disease (CD) have a high inflammatory burden, which can result in irreversible complications and therefore require urgent treatment. However, the speed of onset of efficacy of a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d277a1fa84b6aa7bf688dcda11c8494f
https://doi.org/10.1093/ecco-jcc/jjac190.0094
Zobrazit plný text záznamu
5
P649 The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study
Autor: M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v: Journal of Crohn's and Colitis. 16:i562-i565
Background The coronavirus disease 2019 (COVID-19) pandemic raised concerns among patients with ulcerative colitis (UC) and Crohn’s disease (CD) fearing an increased susceptibility to infection and increased risk of poor outcomes. Furthermore, the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::235ce8f40310b937c4f7b02a2c8c03e2
https://doi.org/10.1093/ecco-jcc/jjab232.771
Zobrazit plný text záznamu
6
DOP23 Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort study
Autor: M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch
Publikováno v: Journal of Crohn's and Colitis. 16:i072-i074
Background The vast majority of patients with ulcerative colitis (UC) and Crohn’s disease (CD) who acquire coronavirus disease 2019 (COVID-19) survive the infection. Still, the long-term health consequences of COVID-19 are not well described in pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e6cfd02b396dbbf5f6264d91c87adc6
https://doi.org/10.1093/ecco-jcc/jjab232.062
Zobrazit plný text záznamu
7
P158 Intestinal Ultrasound at IBD diagnosis predicts surgery – a Copenhagen IBD cohort study
Autor: G R Madsen, M Attauabi, R Wilkens, J F K F Ilvemark, K Theede, J T Bjerrum, F Bendtsen, J B Seidelin, T Boysen, J Burisch
Publikováno v: Journal of Crohn's and Colitis. 17:i317-i318
Background The disease course of inflammatory bowel disease (IBD) is heterogeneous and unpredictable. Currently, we are unable to predict which patients will need IBD-related bowel resection in the first year after diagnosis. Intestinal Ultrasound (I
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac8e0681fe145f9b8fe5033394f27707
https://doi.org/10.1093/ecco-jcc/jjac190.0288
Zobrazit plný text záznamu
8
P583 Tofacitinib for acute severe ulcerative colitis: a systematic review
Autor: P D Ovesen, J Brynskov, J B Seidelin, C Steenholt
Publikováno v: Journal of Crohn's and Colitis. 17:i711-i712
Background Treatment of acute severe ulcerative colitis (ASUC) comprising iv steroids, second line infliximab or cyclosporin, and finally colectomy, has remained unchanged for nearly two decades and without improvements in colectomy rates. Tofacitini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63c627f0ff6a33fa3e911af8544585f5
https://doi.org/10.1093/ecco-jcc/jjac190.0713
Zobrazit plný text záznamu
9
P530 Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
Autor: M Attauabi, G R Madsen, F Bendtsen, J B Seidelin, J Burisch
Publikováno v: Journal of Crohn's and Colitis. 16:i483-i484
Background Several studies have indicated a reduced efficacy of vedolizumab among patients with ulcerative colitis (UC) and Crohn’s disease (CD) previously exposed to biological therapies. The purpose of this study was to determine the efficacy and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62f2d532800454038628c36b682659de
https://doi.org/10.1093/ecco-jcc/jjab232.657
Zobrazit plný text záznamu
10
P639 Incidence and disease presentation of inflammatory bowel disease in Denmark: initial findings from a Copenhagen IBD Inception Cohort Study
Autor: M Dorn-Rasmussen, M Attauabi, G R Madsen, A V Wewer, S Jansson, M M Knudsen, R Wilkens, J F K F Ilvemark, J W Bjerrum, K Theede, F Bendtsen, B Trine, J B Seidelin, J M Burisch
Publikováno v: Journal of Crohn's and Colitis. 16:i556-i557
Background Denmark has one of the highest occurrences of inflammatory bowel disease (IBD) in the world, with reported incidence rates of 7.2 and 6.2 in paediatric ulcerative colitis (pUC) and 10 and 9.4 per 105 for girls and boys in Crohn’s disease
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67e790afa7740f59ad39ea13c39bd20a
https://doi.org/10.1093/ecco-jcc/jjab232.761
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje